Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Analysis of Income Taxes

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Income Tax Expense (Benefit)

Gilead Sciences Inc., income tax expense (benefit), continuing operations

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Federal
State
Foreign
Current
Federal
State
Foreign
Deferred
Income tax expense

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The income tax expense exhibits fluctuating behavior over the five-year period. Current tax expense generally decreased from 2021 to 2025, while deferred tax expense demonstrated significant volatility, shifting from a benefit to an expense and then back to a benefit. The overall income tax expense shows a considerable decrease in later years, followed by an increase in the final year.

Current Tax Expense
Current tax expense began at US$2,189 million in 2021, increased to US$2,803 million in 2022, then decreased to US$2,242 million in 2023 and US$2,053 million in 2024. A substantial decline is observed in 2025, falling to US$1,127 million. This suggests a reduction in taxable income or changes in applicable tax rates over time.
Deferred Tax Expense
Deferred tax expense was a benefit of US$112 million in 2021. It then became a significant expense of US$1,555 million in 2022, followed by an expense of US$995 million in 2023 and US$1,842 million in 2024. In 2025, it reversed to a benefit of US$159 million. This volatility likely reflects changes in temporary differences between book and tax bases of assets and liabilities, or changes in tax laws impacting deferred tax assets and liabilities.
Total Income Tax Expense
Total income tax expense started at US$2,077 million in 2021, decreased substantially to US$1,248 million in 2022, and remained relatively stable at US$1,247 million in 2023. A significant decrease occurred in 2024, with expense falling to US$211 million. However, the expense increased again in 2025, reaching US$1,286 million. The overall trend indicates a decrease in tax expense, with a notable rebound in the final year.

The interplay between current and deferred tax components significantly influences the overall income tax expense. The large fluctuations in deferred tax expense contribute to the overall volatility observed in the total income tax expense. The increase in total income tax expense in 2025, despite the decrease in current tax expense, is attributable to the shift in deferred tax from an expense to a benefit.


Effective Income Tax Rate (EITR)

Gilead Sciences Inc., effective income tax rate (EITR) reconciliation

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
U.S. federal statutory tax rate
Effective tax rate

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The effective income tax rate exhibited considerable fluctuation over the five-year period. While the U.S. federal statutory tax rate remained constant at 21.00%, the effective tax rate demonstrated a decreasing trend initially, followed by a significant increase and subsequent decline.

Initial Decline (2021-2023)
The effective tax rate decreased from 25.10% in 2021 to 18.20% in 2023. This suggests a potential shift in the composition of income sources, with a greater proportion originating from jurisdictions with lower tax rates, or the benefit of tax credits and deductions increasing over this period. It is also possible that changes in the mix of taxable income, such as an increase in foreign-sourced income, contributed to this decline.
Subsequent Increase (2023-2024)
A substantial increase in the effective tax rate was observed in 2024, rising to 30.50%. This represents a significant departure from the prior trend and could be attributable to several factors. These include a change in the geographic distribution of profits, the expiration of previously utilized tax benefits, or a one-time tax expense impacting the period. Further investigation would be required to pinpoint the specific drivers of this increase.
Final Decline (2024-2025)
The effective tax rate experienced a marked decrease in 2025, falling to 13.10%. This reversal of the 2024 increase suggests the factors driving the prior year’s rise were either temporary in nature or were offset by other tax-reducing events. Potential explanations include the realization of deferred tax assets, changes in tax laws, or a shift back towards income sources benefiting from lower tax rates.
Overall Volatility
The considerable variance in the effective tax rate over the five-year period indicates a sensitivity to underlying changes in the company’s financial and operational activities. The difference between the effective tax rate and the statutory rate throughout the period suggests the presence of permanent and temporary differences impacting the company’s tax obligations. Continued monitoring of the effective tax rate and its underlying components is recommended.

Components of Deferred Tax Assets and Liabilities

Gilead Sciences Inc., components of deferred tax assets and liabilities

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net operating loss carryforwards
Stock-based compensation
Reserves and accruals not currently deductible
Excess of tax basis over book basis of intangible assets
Deductible acquired IPR&D payments
Research and other credit carryforwards
Equity investments
Liability related to future royalties
Capitalized R&D expenditures
Capital losses
Other, net
Deferred tax assets before valuation allowance
Valuation allowance
Deferred tax assets
Property, plant and equipment
Excess of book basis over tax basis of intangible assets
Equity investments
Other
Deferred tax liabilities
Net deferred tax assets (liabilities)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The composition of deferred tax assets and liabilities exhibits significant fluctuations over the five-year period. A notable shift occurs from net deferred tax liabilities to net deferred tax assets towards the end of the period, indicating a changing tax profile for the company.

Net Operating Loss Carryforwards
Net operating loss carryforwards generally decreased from US$413 million in 2021 to US$266 million in 2025. While there was a slight increase in 2022, the overall trend is downward, suggesting a diminishing ability to offset future taxable income with past losses.
Significant Deferred Tax Asset Components
Deductible acquired IPR&D payments consistently represent a substantial portion of the deferred tax assets, remaining relatively stable between US$1,271 million and US$1,312 million. Reserves and accruals not currently deductible also contribute significantly, fluctuating between US$644 million and US$700 million. Capitalized R&D expenditures show a dramatic increase beginning in 2022, rising to US$2,173 million in 2024 before decreasing to US$1,773 million in 2025, becoming a major component of deferred tax assets.
Valuation Allowance
The valuation allowance against deferred tax assets increased from US$520 million in 2021 to US$1,217 million in 2024, indicating growing uncertainty regarding the realization of some deferred tax assets. However, it decreased substantially to US$676 million in 2025, potentially reflecting increased confidence in future taxable income.
Deferred Tax Liability Drivers
The primary driver of deferred tax liabilities is the excess of book basis over tax basis of intangible assets, which decreased from US$6,719 million in 2021 to US$3,209 million in 2025. This reduction is a key factor in the overall decrease in deferred tax liabilities. Other deferred tax liabilities remain relatively stable.
Net Deferred Tax Position
The company transitioned from a net deferred tax liability of US$3,017 million in 2021 to a net deferred tax asset of US$1,562 million in 2025. This shift is primarily attributable to the decrease in liabilities related to intangible assets and the increase in capitalized R&D expenditures contributing to deferred tax assets. The period between 2022 and 2023 shows a significant improvement in the net deferred tax position, moving from a liability of US$1,432 million to US$392 million.
Other Notable Items
Capital losses increased significantly in 2024 to US$590 million, contributing to deferred tax assets, but decreased to US$187 million in 2025. Research and other credit carryforwards also increased substantially in 2024, peaking at US$428 million, before decreasing to US$353 million in 2025. Equity investments show volatility, with an increase in 2022 and 2023, followed by a decrease in 2025.

Overall, the changes in deferred tax assets and liabilities suggest a dynamic tax position influenced by factors such as acquisitions, research and development activities, and the utilization of net operating losses. The reduction in intangible asset basis and increased capitalization of R&D appear to be the most significant contributors to the shift from net liabilities to net assets.


Deferred Tax Assets and Liabilities, Classification

Gilead Sciences Inc., deferred tax assets and liabilities, classification

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Deferred tax asset
Deferred tax liability

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The deferred tax asset balance decreased from 2021 to 2023, then increased significantly in 2024 before decreasing again in 2025. Conversely, the deferred tax liability exhibited a substantial decrease from 2021 to 2025.

Deferred Tax Asset Trend
The deferred tax asset decreased from US$1,339 million in 2021 to US$1,196 million in 2023, representing a cumulative decline of approximately 10.7%. A notable increase occurred in 2024, with the asset rising to US$2,378 million. However, this increase was partially offset in 2025, with the asset decreasing to US$1,964 million. The fluctuations suggest potential changes in the recognition of future deductible temporary differences or changes in tax planning strategies.
Deferred Tax Liability Trend
A consistent downward trend is observed in the deferred tax liability. It decreased from US$4,356 million in 2021 to US$2,673 million in 2022, a reduction of approximately 38.6%. This decline continued through 2023, reaching US$1,588 million, and further decreased to US$724 million in 2024 and US$402 million in 2025. This substantial reduction indicates a decrease in taxable temporary differences or a realization of previously recognized deferred tax liabilities.
Net Deferred Tax Position
The net deferred tax position (liability less asset) has shifted considerably. In 2021, the net deferred tax liability was US$3,017 million (US$4,356 - US$1,339). By 2025, this had decreased to US$1,562 million (US$402 - US$1,964). This represents a significant reduction in the overall deferred tax obligation.

The contrasting trends in deferred tax assets and liabilities suggest a dynamic tax profile. The significant changes observed in both balances warrant further investigation into the underlying causes, such as changes in tax laws, accounting methods, or business operations.


Adjustments to Financial Statements: Removal of Deferred Taxes

Gilead Sciences Inc., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Adjustment to Total Assets
Total assets (as reported)
Less: Noncurrent deferred tax assets, net
Total assets (adjusted)
Adjustment to Total Liabilities
Total liabilities (as reported)
Less: Noncurrent deferred tax liabilities, net
Total liabilities (adjusted)
Adjustment to Total Gilead Stockholders’ Equity
Total Gilead stockholders’ equity (as reported)
Less: Net deferred tax assets (liabilities)
Total Gilead stockholders’ equity (adjusted)
Adjustment to Net Income Attributable To Gilead
Net income attributable to Gilead (as reported)
Add: Deferred income tax expense (benefit)
Net income attributable to Gilead (adjusted)

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial information reveals adjustments made to reported figures, primarily concerning the removal of deferred tax assets and liabilities. These adjustments impact total assets, total liabilities, stockholders’ equity, and net income over the five-year period from 2021 to 2025. A consistent pattern emerges where adjusted figures differ from reported figures, suggesting a material impact from these tax-related adjustments.

Total Assets
Reported total assets decreased from US$67,952 million in 2021 to US$58,995 million in 2024, before a slight increase to US$59,023 million in 2025. Adjusted total assets exhibit a similar trend, declining from US$66,613 million in 2021 to US$56,617 million in 2024, and then increasing to US$57,059 million in 2025. The difference between reported and adjusted assets remains relatively consistent across the period, indicating a systematic reduction in asset values upon removing deferred tax effects. The magnitude of the adjustment ranges from approximately US$1.3 billion to US$1.5 billion annually.
Total Liabilities
Reported total liabilities decreased from US$46,888 million in 2021 to US$39,749 million in 2024, followed by a decrease to US$36,405 million in 2025. Adjusted total liabilities follow a similar pattern, decreasing from US$42,532 million in 2021 to US$39,025 million in 2024, and then to US$36,003 million in 2025. The adjustments to liabilities are also consistent, ranging from approximately US$3.3 billion to US$4.2 billion annually, suggesting a significant portion of reported liabilities are related to deferred tax obligations.
Stockholders’ Equity
Reported stockholders’ equity fluctuated over the period, increasing from US$21,069 million in 2021 to US$22,833 million in 2023, then decreasing to US$19,330 million in 2024, and increasing again to US$22,703 million in 2025. Adjusted stockholders’ equity shows a different trend, increasing from US$24,086 million in 2021 to US$23,225 million in 2023, decreasing to US$17,676 million in 2024, and increasing to US$21,141 million in 2025. The adjustments consistently increase stockholders’ equity, with the largest impact observed in 2021 and 2024, ranging from approximately US$1.4 billion to US$5.0 billion annually. This suggests the deferred tax items negatively impact the reported equity position.
Net Income
Reported net income attributable to the company varied considerably, peaking at US$6,225 million in 2021, decreasing to US$480 million in 2024, and then increasing substantially to US$8,510 million in 2025. Adjusted net income also fluctuates, but to a lesser extent. It decreased from US$6,113 million in 2021 to US$3,037 million in 2022, then to US$4,670 million in 2023, decreased significantly to a loss of US$1,362 million in 2024, and increased to US$8,669 million in 2025. The adjustments to net income are most pronounced in 2022 and 2024, reducing reported income by US$1,555 million and resulting in an additional loss of US$1,842 million, respectively. This indicates that deferred tax expenses or benefits have a substantial impact on the reported profitability.

In summary, the removal of deferred tax items consistently alters the reported financial position and performance. The adjustments impact all key financial statement elements, suggesting a significant deferred tax position. The magnitude of these adjustments warrants further investigation to understand the underlying tax strategies and their implications for the company’s financial health.


Gilead Sciences Inc., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Deferred Taxes (Summary)

Gilead Sciences Inc., adjusted financial ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Profit Margin
Reported net profit margin
Adjusted net profit margin
Total Asset Turnover
Reported total asset turnover
Adjusted total asset turnover
Financial Leverage
Reported financial leverage
Adjusted financial leverage
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The financial performance metrics exhibit notable variations when analyzed with and without the impact of deferred taxes. Generally, the adjusted ratios present a more conservative view of profitability and returns compared to their reported counterparts. Several key trends emerge across the five-year period.

Profitability
Reported net profit margin demonstrates volatility, decreasing from 23.05% in 2021 to 17.02% in 2022, increasing to 21.03% in 2023, then plummeting to 1.68% in 2024 before a substantial recovery to 29.43% in 2025. The adjusted net profit margin mirrors this pattern but with lower overall values and a negative result in 2024 (-4.76%), indicating a more pronounced impact from deferred tax adjustments during that year. The difference between reported and adjusted margins widens in years with significant deferred tax effects.
Asset Utilization
Reported total asset turnover shows a gradual increase from 0.40 in 2021 to 0.49 in 2025, suggesting improving efficiency in asset utilization. The adjusted total asset turnover follows a similar upward trend, consistently remaining slightly higher than the reported value. The difference between the two remains relatively stable across the period.
Financial Leverage
Reported financial leverage fluctuates, decreasing from 3.23 in 2021 to 2.60 in 2025. The adjusted financial leverage exhibits a similar decreasing trend initially, but increases to 3.20 in 2024 before decreasing again. The adjusted leverage is consistently lower than the reported leverage, suggesting that deferred taxes contribute to an inflated leverage ratio when not adjusted for.
Returns on Equity (ROE)
Reported ROE mirrors the volatility of the net profit margin, declining from 29.55% in 2021 to 2.48% in 2024, then surging to 37.48% in 2025. The adjusted ROE demonstrates a similar pattern but with lower values and a negative result in 2024 (-7.71%). The disparity between reported and adjusted ROE is substantial, particularly in 2024 and 2025, highlighting the significant influence of deferred taxes on equity returns.
Returns on Assets (ROA)
Reported ROA follows a similar trajectory to ROE, decreasing from 9.16% in 2021 to 0.81% in 2024, and then increasing to 14.42% in 2025. The adjusted ROA also exhibits this pattern, but with lower values and a negative result in 2024 (-2.41%). The difference between reported and adjusted ROA is less pronounced than the difference observed in ROE, but still indicates a material impact from deferred tax adjustments.

In summary, the removal of deferred tax effects consistently results in lower profitability and return ratios. The year 2024 stands out as a period where deferred taxes significantly impacted the reported financial performance, leading to substantial differences between the reported and adjusted ratios. The adjusted ratios provide a potentially more realistic assessment of underlying financial performance by excluding the timing differences associated with deferred taxes.


Gilead Sciences Inc., Financial Ratios: Reported vs. Adjusted


Adjusted Net Profit Margin

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead
Product sales
Profitability Ratio
Net profit margin1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead
Product sales
Profitability Ratio
Adjusted net profit margin2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Net profit margin = 100 × Net income attributable to Gilead ÷ Product sales
= 100 × ÷ =

2 Adjusted net profit margin = 100 × Adjusted net income attributable to Gilead ÷ Product sales
= 100 × ÷ =


The period under review demonstrates considerable fluctuation in both reported and adjusted net income attributable to the company. Consequently, the associated net profit margins exhibit corresponding variability. A detailed examination of the adjusted net profit margin reveals specific trends and points of interest.

Adjusted Net Profit Margin Trend (2021-2025)
The adjusted net profit margin began at 22.63% in 2021, declining significantly to 11.26% in 2022. A partial recovery was observed in 2023, with the margin reaching 17.34%. However, 2024 witnessed a substantial downturn, resulting in a negative adjusted net profit margin of -4.76%. The final year of the period, 2025, showed a strong rebound, with the adjusted net profit margin increasing to 29.98%.
Comparison with Reported Net Profit Margin
The adjusted net profit margin generally tracks the reported net profit margin, but with greater volatility. While both margins decreased from 2021 to 2022 and increased from 2022 to 2023, the adjusted margin experienced a more pronounced decline in 2024, falling into negative territory compared to the reported margin’s 1.68%. The substantial increase in both margins in 2025 suggests a strong performance in that year, with the adjusted margin slightly exceeding the reported margin.
Key Observations
The significant drop in the adjusted net profit margin in 2024 warrants further investigation. The negative value indicates that, after adjustments, the company experienced a net loss on its revenue. The substantial recovery in 2025 suggests the impact of the factors contributing to the 2024 loss were either mitigated or reversed. The difference between the reported and adjusted net income suggests that adjustments are having a material impact on the company’s profitability picture, and the nature of these adjustments should be examined.

Overall, the adjusted net profit margin demonstrates a pattern of instability over the five-year period. While the final year shows a positive outcome, the preceding fluctuations highlight potential underlying issues affecting profitability that require further scrutiny.


Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Product sales
Total assets
Activity Ratio
Total asset turnover1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Product sales
Adjusted total assets
Activity Ratio
Adjusted total asset turnover2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Total asset turnover = Product sales ÷ Total assets
= ÷ =

2 Adjusted total asset turnover = Product sales ÷ Adjusted total assets
= ÷ =


The analysis reveals trends in both reported and adjusted total assets, alongside their corresponding turnover ratios, over a five-year period. Reported total assets generally decreased from 2021 to 2024, before exhibiting a slight increase in 2025. Adjusted total assets mirrored this pattern, with a similar decrease from 2021 to 2024 followed by a modest rise in 2025.

Reported Total Assets
Reported total assets decreased from US$67,952 million in 2021 to US$58,995 million in 2024, representing a cumulative decline of approximately 13.2%. A minor increase to US$59,023 million was observed in 2025.
Adjusted Total Assets
Adjusted total assets followed a similar trajectory, declining from US$66,613 million in 2021 to US$56,617 million in 2024, a decrease of roughly 15.1%. The value increased slightly to US$57,059 million in 2025.
Reported Total Asset Turnover
The reported total asset turnover ratio demonstrated an increasing trend over the period. Starting at 0.40 in 2021, it rose to 0.43 in both 2022 and 2023, and further increased to 0.48 in 2024 before stabilizing at 0.49 in 2025. This indicates improving efficiency in generating sales from reported assets.
Adjusted Total Asset Turnover
The adjusted total asset turnover ratio exhibited a pattern comparable to the reported ratio. It increased from 0.41 in 2021 to 0.44 in both 2022 and 2023, then rose to 0.51 in 2024 and remained constant at 0.51 in 2025. The adjusted ratio consistently exceeded the reported ratio throughout the observed period, suggesting that excluding certain asset components results in a more favorable efficiency metric.

The consistent increase in both reported and adjusted total asset turnover ratios, despite the overall decrease in asset values, suggests that the company is becoming more effective at utilizing its assets to generate revenue. The slight increases in total assets in 2025 do not appear to have negatively impacted this trend.


Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Total assets
Total Gilead stockholders’ equity
Solvency Ratio
Financial leverage1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted total assets
Adjusted total Gilead stockholders’ equity
Solvency Ratio
Adjusted financial leverage2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 Financial leverage = Total assets ÷ Total Gilead stockholders’ equity
= ÷ =

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Gilead stockholders’ equity
= ÷ =


An examination of the financial information reveals trends in both reported and adjusted financial leverage over a five-year period. Total assets experienced a general decline from 2021 to 2024, with a slight increase in 2025. Stockholders’ equity exhibited more fluctuation, decreasing notably in 2024 before recovering in 2025. These movements influence the calculated leverage ratios.

Reported Financial Leverage
Reported financial leverage decreased from 3.23 in 2021 to 2.72 in 2023, indicating a lessening of financial risk based on reported figures. However, it increased to 3.05 in 2024 before decreasing again to 2.60 in 2025. This suggests a period of increased risk in 2024, followed by a return to a lower leverage position.
Adjusted Financial Leverage
Adjusted financial leverage followed a similar pattern to the reported leverage, declining from 2.77 in 2021 to 2.62 in 2023. A more substantial increase was observed in 2024, reaching 3.20, before decreasing to 2.70 in 2025. The adjusted leverage consistently indicates a slightly more conservative financial position than the reported leverage, likely due to the adjustments made to total assets and stockholders’ equity.
Asset Trends
Reported total assets decreased from US$67,952 million in 2021 to US$58,995 million in 2024, before a modest increase to US$59,023 million in 2025. Adjusted total assets mirrored this trend, declining from US$66,613 million to US$56,617 million over the same period, with a similar slight increase in 2025. The consistent decline suggests potential asset sales, depreciation, or write-downs.
Equity Trends
Reported total stockholders’ equity increased from US$21,069 million in 2021 to US$22,833 million in 2023, then decreased significantly to US$19,330 million in 2024, and recovered to US$22,703 million in 2025. Adjusted stockholders’ equity showed a similar pattern, with a decrease in 2024 and a subsequent recovery in 2025. These fluctuations in equity could be attributed to factors such as net income, dividends, and share repurchases.

The divergence between reported and adjusted figures suggests that the adjustments to assets and equity have a material impact on the calculated financial leverage. The increase in both reported and adjusted leverage in 2024 warrants further investigation to understand the underlying drivers of this change.


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead
Total Gilead stockholders’ equity
Profitability Ratio
ROE1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead
Adjusted total Gilead stockholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROE = 100 × Net income attributable to Gilead ÷ Total Gilead stockholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Adjusted net income attributable to Gilead ÷ Adjusted total Gilead stockholders’ equity
= 100 × ÷ =


The period between 2021 and 2025 demonstrates considerable fluctuation in both reported and adjusted net income, impacting return on equity calculations. Reported net income decreased significantly from 2021 to 2022, recovered in 2023, experienced a substantial decline in 2024, and then rose sharply in 2025. Adjusted net income followed a similar pattern, though the magnitude of the decline in 2024 was more pronounced, resulting in a negative value. Stockholders’ equity, both reported and adjusted, also exhibited variability over the five-year period.

Reported Return on Equity (ROE)
Reported ROE mirrored the trends in reported net income. It decreased from 29.55% in 2021 to 21.62% in 2022, increased to 24.81% in 2023, plummeted to 2.48% in 2024, and then surged to 37.48% in 2025. This volatility suggests a sensitivity of the reported ROE to changes in net income.
Adjusted Return on Equity (ROE)
Adjusted ROE also showed significant fluctuations. It decreased from 25.38% in 2021 to 13.40% in 2022, increased to 20.11% in 2023, became negative at -7.71% in 2024, and then increased substantially to 41.01% in 2025. The negative adjusted ROE in 2024 is a notable observation, indicating that adjusted net income was insufficient to generate a return on the adjusted equity base. The adjusted ROE generally trends lower than the reported ROE across the period.
Equity Trends
Reported total stockholders’ equity increased modestly from 2021 to 2023, then decreased substantially in 2024 before partially recovering in 2025. Adjusted total stockholders’ equity followed a similar pattern, though the fluctuations were less extreme. The difference between reported and adjusted equity values is consistent throughout the period, suggesting systematic adjustments are being made.

The substantial swings in both net income and ROE, particularly the negative adjusted net income and ROE in 2024, warrant further investigation. The significant increase in both reported and adjusted ROE in 2025, while positive, also requires scrutiny to understand the underlying drivers of this improvement.


Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Gilead
Total assets
Profitability Ratio
ROA1
Adjusted for Deferred Taxes
Selected Financial Data (US$ in millions)
Adjusted net income attributable to Gilead
Adjusted total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

2025 Calculations

1 ROA = 100 × Net income attributable to Gilead ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Adjusted net income attributable to Gilead ÷ Adjusted total assets
= 100 × ÷ =


The period between 2021 and 2025 demonstrates considerable fluctuation in reported and adjusted net income, impacting return on assets calculations. Reported net income decreased significantly from 2021 to 2022, recovered in 2023, experienced a substantial decline in 2024, and then rose sharply in 2025. Adjusted net income followed a similar pattern, though the magnitude of the decline in 2024 was more pronounced, resulting in a negative value. Total assets, both reported and adjusted, generally decreased over the five-year period, with a slight increase in reported total assets in 2025.

Reported Return on Assets (ROA)
Reported ROA mirrored the trend in reported net income. It decreased from 9.16% in 2021 to 7.27% in 2022, increased to 9.12% in 2023, plummeted to 0.81% in 2024, and then surged to 14.42% in 2025. This volatility suggests a strong sensitivity of reported ROA to changes in net income.
Adjusted Return on Assets (ROA)
Adjusted ROA also exhibited significant variation. Starting at 9.18% in 2021, it fell to 4.90% in 2022, rose to 7.66% in 2023, then dropped to -2.41% in 2024. A substantial recovery was observed in 2025, with adjusted ROA reaching 15.19%. The negative value in 2024 indicates that adjusted net income was insufficient to generate a return on adjusted assets. The difference between reported and adjusted ROA suggests that certain items significantly impact net income and, consequently, ROA.

The divergence between reported and adjusted figures, particularly in 2024, warrants further investigation to understand the nature of the adjustments made. The substantial increase in both reported and adjusted ROA in 2025, coupled with the slight increase in reported total assets, indicates a significant improvement in profitability during that year. The overall trend highlights the importance of considering both reported and adjusted metrics when evaluating financial performance.